Evidence map›Paper›PMID 34677153›Full record

Trial reportMedical gas research

Ozone gas applied through nebulization as adjuvant treatment for lung respiratory diseases due to COVID-19 infections: a prospective randomized trial.

Erhan Dengiz, Çağrı Özcan, Yusuf İzzettin Güven, Selcen Uçar, Behçet Kemal Ener, Semih Sözen, Buket Yağcı, İnal Albek Güzel, Betül Yiğit, Aslınur Andaç and 4 more

Open access · hybridAbstract readRandomized Controlled Trial
In one paragraph

Trial report in Medical gas research. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed, 1 pooled it
1.9field-weighted citation impact, top 16% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed, 1 synthesis or guideline pooled it, 11 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Review
  4. Article
  5. Article
  6. Review
  7. Review
  8. Review
  9. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors at 3 institutions in 1 country.

Erhan DengizEdis Pharma Pharmaceutical Industry, Istanbul, Turkey.
Çağrı ÖzcanHealth Science Univercity, Umraniye Training and Research Hospital, Istanbul, Turkey.
Yusuf İzzettin GüvenDr. Feriha Öz Emergency Hospital, İstanbul, Turkey.
Selcen UçarDr. Feriha Öz Emergency Hospital, İstanbul, Turkey.
Behçet Kemal EnerHealth Science Univercity, Umraniye Training and Research Hospital, Istanbul, Turkey.
Semih SözenPendik State Hospital, İsttanbul, Turkey.
Buket YağcıHealth Science Univercity, Haydarpasa Training and Research Hospital, İstanbul, Turkey.
İnal Albek GüzelDr. Feriha Öz Emergency Hospital, İstanbul, Turkey.
Betül YiğitDr. Feriha Öz Emergency Hospital, İstanbul, Turkey.
Aslınur AndaçPendik State Hospital, İsttanbul, Turkey.
Beyza GüneşPendik State Hospital, İsttanbul, Turkey.
Emire BorEdis Pharma Pharmaceutical Industry, Istanbul, Turkey.
Uğur KarabudakEdis Pharma Pharmaceutical Industry, Istanbul, Turkey.
Ali KayaEdis Pharma Pharmaceutical Industry, Istanbul, Turkey.
Acıbadem Adana Hospital · TRÜmraniye Eğitim ve Araştırma Hastanesi · TRHaydarpaşa Numune Eğitim ve Araştırma Hastanesi · TR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The objective of this study was to provide lung disinfection by nebulizing ozone gas with distilled water and olive oil for patients who have clinical symptoms due to coronavirus disease 2019 (COVID-19). The study attempted to reduce the viral load of COVID-19 in the lungs of patients, to provide a faster response to medical treatment. Between August 2020 and September 2020, 30 patients who met the study criteria were prospectively evaluated. There were 2 groups with 15 patients in each group: patients in control group were not treated with ozone and only received standard COVID-19 treatment; patients in ozone group received lung disinfection technique with ozone and standard COVID-19 treatment. A statistically significant difference was found in the length of stay in hospital, change in C-reactive protein, polymerase chain reaction results after 5 days, and computed tomography scores between two groups. There was no statistically significant difference in D-dimer, urea, lactate dehydrogenase, lymphocyte, leukocyte, and platelet between two groups. According to the data, we think that the lung disinfection technique applied with ozone inhalation reduces the rate of pneumonia in COVID-19 patients and makes the patients respond faster to the treatment and become negative according to the polymerase chain reaction tests. The study was approved by the Ethical Committee of the Istanbul Medipol University Clinical Trials (approval No. 0011) on July 2, 2020.

Indexed as

COVID-19 Drug TreatmentOzoneHumansLungProspective StudiesSARS-CoV-2Treatment OutcomeOzonecoronavirusCOVID-19lung disinfectionmedical ozone gasozone gasozone inhalationozone therapypulmonary diseaseviral puenmonia

Identifiers

PMID34677153
PMCPMC8562398
OpenAlexW3206032042

What Socratic holds

Textmetadata
LicenceCC BY-NC-SA
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.